Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.60 |
| ▸ | HTR1A | P08908 | 1/20 | 0.60 |
| ▸ | DRD1 | P21728 | 1/20 | 0.60 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.60 |
| ▸ | DRD3 | P35462 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 4/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.56 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.56 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.56 |
| ▸ | SCN1A | P35498 | 1/20 | 0.56 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.56 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8186813 | 1.00 | ADRA2A (0.60) | ADRA2AADRA1AHTR1ADRD1TBXA2R | |
| SCHEMBL407540 | 1.00 | ADRA2A (0.60) | ADRA2AADRA1AHTR1ADRD1TBXA2R | |
| SCHEMBL31407451 | 1.00 | ADRA2A (0.60) | ADRA2AADRA1AHTR1ADRD1TBXA2R | |
| SCHEMBL29841237 | 1.00 | ADRA2A (0.60) | ADRA2AADRA1AHTR1ADRD1TBXA2R | |
| Hydrochloric Acid SCHEMBL783118 | 0.98 | ADRA2A (0.58) | ADRA2AADRA1AHTR1ADRD1TBXA2R | |
| Bromide SCHEMBL11489853 | 0.98 | ADRA2A (0.58) | ADRA2AADRA1AHTR1ADRD1TBXA2R | |
| SCHEMBL406531 | 0.85 | HTT (0.61) | ADRA2AADRA1AHTR1ADRD1TBXA2R | |
| Hydrochloric Acid SCHEMBL8179101 | 0.83 | HTT (0.59) | ADRA2AADRA1AHTR1ADRD1TBXA2R | |
| SCHEMBL568115 | 0.80 | ADRA2A (0.60) | ADRA2AADRA1AHTR1ADRD1TBXA2R | |
| SCHEMBL11484814 | 0.80 | ADRA2A (0.56) | ADRA2AADRA1AHTR1ADRD1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12291533-B2 | Substituted fused pyrimidine compounds and uses thereof | NORTHWESTERN UNIVERSITY (US) | 2025-05-06 | — | — | US | disclosed |
| US-20200283444-A1 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS AND USES THEREOF | NORTHWESTERN UNIVERSITY | 2020-09-10 | — | — | US | disclosed |
| US-20200283444-A1 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS AND USES THEREOF | NORTHWESTERN UNIVERSITY | 2020-09-10 | — | — | US | disclosed |
| WO-2019027765-A1 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS AND USES THERE | NORTHWESTERN UNIVERSITY (US) | 2019-02-07 | — | — | WO | disclosed |
| EP-2847178-B1 | DERIVATIVES OF DOCOSAHEXAENOYLETHANOLAMIDE AND USES THEREOF | US HEALTH (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-1768970-B1 | SULFAMATE AND SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-09 | — | — | EP | disclosed |
| US-9012466-B2 | Substituted tricyclic pyrazolo-pyrimidine compounds | ARQULE INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-9012466-B2 | Substituted tricyclic pyrazolo-pyrimidine compounds | ARQULE INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-8937096-B2 | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-20 | — | — | US | disclosed |
| WO-2014164729-A1 | SUBSTITUTED TRICYCLIC PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-5658941-A | PSYCHOLOGICAL DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-08-19 | — | — | US | disclosed |
| US-5559143-A | Serotonin 5HT1A agonistic method | MERRELL PHARMACEUTICALS INC. (US) | 1996-09-24 | — | — | US | disclosed |
| US-5496847-A | ANXIOLYTIC AND ANTIDEPRESSANT | BRISTOL-MYERS SQUIBB CO. (US) | 1996-03-05 | — | — | US | disclosed |
| EP-0520674-B1 | Antipsychotic benzodioxan derivatives | AMERICAN HOME PROD (US) | 1995-08-16 | — | — | EP | disclosed |
| US-5391570-A | Anxiolytic agents; antidepressants | BRISTOL-MYERS SQUIBB (US) | 1995-02-21 | — | — | US | disclosed |
| US-5387604-A | 1,4 benzodioxin derivatives and their use as serotonin 5HT1A agonists | MERRELL DOW PHARMACEUTICALS INC. (US) | 1995-02-07 | — | — | US | disclosed |
| US-5189179-A | SEROTONIN 5HT1A AGONISTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-02-23 | — | — | US | disclosed |
| EP-0520674-A1 | Antipsychotic benzodioxan derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-12-30 | — | — | EP | disclosed |
| US-5126366-A | Antidepressants, antipsychotics, anxiolytic agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-06-30 | — | — | US | disclosed |
| EP-0478954-A1 | Serotonin 5HT1A and 5HT1D antagonists | MERRELL PHARMACEUTICALS INC. (US) | 1992-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283444-A1 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS AND USES THEREOF | GBA3, GBA1, GBA2 | ADRA2A 2468/4885ADRA1A 2470/4885HTR1A 4200/4885 |
| US-12291533-B2 | Substituted fused pyrimidine compounds and uses thereof | GBA3, GBA1, GBA2 | ADRA2A 2468/4885ADRA1A 2470/4885HTR1A 4200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.